DXC024 / Hangzhou DAC Biotech - LARVOL DELTA

DXC024, a novel anti-TROP2/EGFR bispecific antibody and tubulysin conjugate, for targeted treatment of highly TROP2- or EGFR-expressing tumors (AACR 2024) - "However, the approved Trop2 ADC, sacituzumab govitecan, only showed an objective response rate (ORR) of 17% and median OS of 9.5 months for lung cancers. In vivo, they showed very good durable antitumor response at dose as low as 4.6 mg/Kg for one injection in Calu3 (TROP2highEGFRmoderate) xenograft model, and demonstrated enhanced anti-tumor efficacy in comparison to those of the same payload conjugated to the monoclonal TROP2 or EGFR ADCs. These results indicated that DXC024 would be a promising ADC candidate for targeted treatment of highly either TROP2- or EGFR-expressing tumors."

Lung Cancer • Oncology • Solid Tumor • EGFR • TACSTD2